>
Switch to:

Keros Therapeutics EV-to-EBITDA

: -17.98 (As of Today)
View and export this data going back to 2020. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Keros Therapeutics's enterprise value is $884.12 Mil. Keros Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 was $-49.16 Mil. Therefore, Keros Therapeutics's EV-to-EBITDA for today is -17.98.

NAS:KROS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -40.02   Med: -26.88   Max: -11.47
Current: -17.98

-40.02
-11.47

During the past 3 years, the highest EV-to-EBITDA of Keros Therapeutics was -11.47. The lowest was -40.02. And the median was -26.88.

NAS:KROS's EV-to-EBITDA is ranked lower than
99.99% of the 302 Companies
in the Biotechnology industry.

( Industry Median: 27.27 vs. NAS:KROS: -17.98 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2021-05-16), Keros Therapeutics's stock price is $48.87. Keros Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $-2.39. Therefore, Keros Therapeutics's PE Ratio for today is .

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Keros Therapeutics EV-to-EBITDA Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keros Therapeutics Annual Data
Dec18 Dec19 Dec20
EV-to-EBITDA - - -30.19

Keros Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -21.10 -17.22 -30.19 -23.96

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Keros Therapeutics EV-to-EBITDA Distribution

* The bar in red indicates where Keros Therapeutics's EV-to-EBITDA falls into.



Keros Therapeutics EV-to-EBITDA Calculation

Keros Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=884.115/-49.162
=-17.98

Keros Therapeutics's current Enterprise Value is $884.12 Mil.
Keros Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 was -10.846 (Jun. 2020 ) + -11.962 (Sep. 2020 ) + -10.6 (Dec. 2020 ) + -15.754 (Mar. 2021 ) = $-49.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Keros Therapeutics  (NAS:KROS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Keros Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=48.87/-2.39
=

Keros Therapeutics's share price for today is $48.87.
Keros Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was -0.62 (Jun. 2020 ) + -0.6 (Sep. 2020 ) + -0.49 (Dec. 2020 ) + -0.68 (Mar. 2021 ) = $-2.39.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Keros Therapeutics EV-to-EBITDA Related Terms


Keros Therapeutics EV-to-EBITDA Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)